Associated Papers
Pharmacogenetics and Molecular Ancestry of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Ecuadorian Subjects with Type 2 Diabetes Mellitus.
Ortega-Ayala A et al.
Pharmaceuticals (basel, Switzerland), 2025
Molecular Ancestry Across Allelic Variants of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Mexican-Mestizo DMT2 Patients.
Ortega-Ayala A et al.
Biomedicines, 2025
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Beyond Single Diagnosis: Exploring Multidiagnostic Realities in Pediatric Patients through Genome Sequencing.
Guo F et al.
Human Mutation, 2024
Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S et al.
Medicine, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Ethnic Diversity and Warfarin Pharmacogenomics.
Asiimwe IG et al.
Frontiers in Pharmacology, 2022
Pharmacogenetic determinants of warfarin in the Indian population.
Naushad SM et al.
Pharmacological Reports : Pr, 2021
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease.
Cacabelos R et al.
Pharmaceuticals (basel, Switzerland), 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients.
Akdeniz CS et al.
Future Cardiology, 2020
Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM et al.
International Journal of Molecular Sciences, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson's Disease.
Cacabelos R et al.
Planta Medica, 2019
Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Langaee T et al.
Genetic Testing and Molecular Biomarkers, 2019
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Kasi PM et al.
Technology in Cancer Research & Treatment, 2019
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.
Mikstacki A et al.
Journal of Applied Genetics, 2017
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Arwood MJ et al.
Clinical Pharmacology and Therapeutics, 2017
Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
Schapkaitz E et al.
Journal of Vascular Nursing : Official Publication of the Society for Peripheral Vascular Nursing, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation.
Goh LL et al.
Plos One, 2017
To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
De Andrés F et al.
Omics : a Journal of Integrative Biology, 2016
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
Duconge J et al.
Plos One, 2016
Pharmacogenetics of healthy volunteers in Puerto Rico.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Baranova EV et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Drozda K et al.
Pharmacogenetics and Genomics, 2015
Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.
Llerena A et al.
The Pharmacogenomics Journal, 2014
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.
Bosch LA
Journal of Pharmacogenomics & Pharmacoproteomics, 2014
[Effect of genetic variations on adjusting of warfarin dose].
Darılmaz Yüce G
Tuberkuloz Ve Toraks, 2014
Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico.
Sosa-Macías M et al.
The Pharmacogenomics Journal, 2013
Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.
Hamberg AK et al.
European Journal of Clinical Pharmacology, 2013
[Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450].
Saldaña-Cruz AM et al.
Revista De Neurologia, 2013
Pharmacogenomics of warfarin in populations of African descent.
Suarez-Kurtz G et al.
British Journal of Clinical Pharmacology, 2013
Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
Allabi AC et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2012
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
Valentin II et al.
The Annals of Pharmacotherapy, 2012
Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population.
Pathare AV et al.
Human Biology, 2012
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing.
Rodríguez-Vélez R et al.
Puerto Rico Health Sciences Journal, 2010
Warfarin dosing in patients with impaired kidney function.
Limdi NA et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 2010
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2010
CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.
Villagra D et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
Maurice CB et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Implementing genotype-guided antithrombotic therapy.
Seip RL et al.
Future Cardiology, 2010